1-20 of 36
Craig E. Cole
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, Ajay K. Nooka, Leonard Heffner, Craig E. Cole, Ravi Vij, J Christine Ye, Craig C Hofmeister, John Rushton, Zhengjia Chen, Subir Goyal, Munevver Cinar, Sagar Lonial, Jonathan L. Kaufman
Journal: Blood
Blood (2022) 140 (Supplement 1): 7311–7312.
https://doi.org/10.1182/blood-2022-170062
Published: 2022
Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, Ajay K. Nooka, Leonard Heffner, Craig E. Cole, Jing C. Ye, Ravi Vij, Craig C. Hofmeister, John Rushton, Zhengjia Chen, Subir Goyal, Jeffrey M. Switchenko, Sagar Lonial, Jonathan L. Kaufman
Journal: Blood
Blood (2021) 138 (Supplement 1): 2758.
https://doi.org/10.1182/blood-2021-153922
Published: 2021
Journal Articles

Antithrombin Supplementation in Adults with Acute Lymphoblastic Leukemia (ALL) Following Asparaginase Therapy: A Meta-Analysis

Osama Mosalem, MBBS, Mark Mujer, MD, Fawzi Abu Rous, MD, Craig E. Cole, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20.
https://doi.org/10.1182/blood-2020-142087
Published: 2020
Journal Articles

Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Christopher T Su, MD, Liying Chen, MS, Jason Chen, MD, Brian Parkin, MD, Avery Polk, Malathi Kandarpa, PhD, Craig E. Cole, MD, Erica Campagnaro, MD, Josh Vo, PhD, Dan Robinson, PhD, Yi-Mi Wu, PhD, Moshe Talpaz, MD, Jennifer Yesil, MSc, Daniel Auclair, P. Leif Bergsagel, MD, Arul Chinnaiyan, MDPhD, Veerabhadran Baladandayuthapani, PhD, J Christine Ye, MDMSc
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-134558
Published: 2020
Journal Articles

Daratumumab (DARA) Plus Carfilzomib, Pomalidomide, Dexamethasone (KPd) in Lenalidomide Refractory Multiple Myeloma (MM): A Multi-Center MMRC Study

Jagoda Jasielec, MD, Jeff Zonder, MD, Benjamin A Derman, MD, Donna E. Reece, MD, Craig E. Cole, MD, Jesus G. Berdeja, MD, Brittany Wolfe, Sarah Major, Kathryn M. Tinari, Andrew Stefka, MS, Fabrizio Fazzi, Megan Whelan, Christine Gleason, Amanda McIver, Evangelia Andreatos, Bernadette M. Libao, Daniel Juergens, Kent Griffith, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50.
https://doi.org/10.1182/blood-2020-141029
Published: 2020
Journal Articles

Financial Burden Is Associated with Postponing Care and Decreasing Physical and Emotional Quality of Life Among Patients with Multiple Myeloma and Chronic Lymphocytic Leukemia

Erica E. Fortune, PhD, Melissa F. Miller, PhD MPH, Elissa C. Kranzler, PhD, Jemeille Ackourey, MPH, Kelly Clark, MA, Heather Badt, MBA, LSS, Linda Bohannon, RN, BSN, MSM, Craig E. Cole, MD, Thomas W. Leblanc, Alexandra K Zaleta, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45.
https://doi.org/10.1182/blood-2020-137050
Published: 2020
Journal Articles

Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study

Ajay K Nooka, MDMPH, Andrew J. Yee, MD, Carol Ann Huff, MD, Dan T. Vogl, MD, Maria Gavriatopoulou, MD, Ajai Chari, MD, Philippe Moreau, MD, David Dingli, MD PhD, Craig E. Cole, MD, Sagar Lonial, Meletios A. Dimopoulos, MD, Joshua R Richter, MD, Ravi Vij, MBBS, Sascha A Tuchman, MD, Marc S Raab, MD PhD, Noa Biran, MD, David S. Siegel, Paul G. Richardson, MD, Jianjun Liu, Anita Joshi, PhD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD, Sundar Jagannath, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1872.
https://doi.org/10.1182/blood-2019-122908
Published: 2019
Journal Articles

Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy

Julia Frede, PhD MPhil, Praveen Anand, PhD, Andrew J. Yee, MD, Tushara Vijaykumar, Monica S. Nair, Johannes M. Waldschmidt, MD, Sayalee V. Potdar, Jake A. Kloeber, Antonis Kokkalis, PhD MSc, Guangwu Guo, PhD, Samantha J. Shapiro, Mason L. Mann, Robb S Friedman, MD, Brea C. Lipe, MD, Erica L. Campagnaro, MD, Craig E. Cole, MD, Elizabeth K. O'Donnell, MD, Thomas Guerrero, MD, Omar Nadeem, MD, Jacob P. Laubach, MD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Noopur Raje, MD, Birgit Knoechel, MD PhD, Jens G. Lohr, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3091.
https://doi.org/10.1182/blood-2019-130247
Published: 2019
Journal Articles

Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients

J Christine Ye, MDMSc, Liying Chen, Jason Chen, MD, Brian Parkin, Avery Polk, Malathi Kandarpa, PhD, Craig E. Cole, MD, Erica L. Campagnaro, MD, Dan Robinson, PhD, Yi-Mi Wu, Moshe Talpaz, MD, Jennifer Yesil, Daniel Auclair, P. Leif Bergsagel, MD, Arul Chinnaiyan, MD, Veerabhadran Baladandayuthapani
Journal: Blood
Blood (2019) 134 (Supplement_1): 4360.
https://doi.org/10.1182/blood-2019-124135
Published: 2019
Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, MD, Ajay K Nooka, MDMPH, Leonard Heffner, MD, Craig E. Cole, MD, J Christine Ye, MDMSc, Ravi Vij, MBBS, Craig C Hofmeister, MDMPH, John Rushton, PhD, Zhengjia Chen, PhD, Zhao Chang, PhD, Munevver Cinar, MD, Daniel Auclair, Sagar Lonial, Jonathan L. Kaufman, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3188.
https://doi.org/10.1182/blood-2019-131223
Published: 2019
Journal Articles

A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Andrew J. Yee, MD, Jacob P. Laubach, MD, Erica L. Campagnaro, MD, Brea C. Lipe, MD, Omar Nadeem, MD, Robb S Friedman, MD, Craig E. Cole, MD, Elizabeth K. O'Donnell, MD, Giada Bianchi, MD, Andrew R. Branagan, MD, Samantha J. Shapiro, Cynthia C. Harrington, NP, Jill N. Burke, NP, Marilyn T. Gammon, RN, Kathleen J. Lively, RN, Cassandra A. Thorburn, Mason L. Mann, Jens G. Lohr, MD PhD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Noopur S. Raje, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3169.
https://doi.org/10.1182/blood-2019-124870
Published: 2019
Journal Articles

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas

Andrew J. Yee, MD, Carol Ann Huff, MD, Ajai Chari, MD, Dan T. Vogl, MD, Maria Gavriatopoulou, MD, Ajay K Nooka, MDMPH, Philippe Moreau, MD, David Dingli, MD PhD, Craig E. Cole, MD, Sagar Lonial, Meletios A. Dimopoulos, MD, Joshua R Richter, MD, Ravi Vij, MBBS, Sascha A Tuchman, MD, James E. Hoffman, MD, Luciano J. Costa, MD PhD, Terri L Parker, MD, Philip Vlummens, MD, Chantal Doyen, MD, Noa Biran, MD, David S. Siegel, Jatin Shah, MD, Carla Picklesimer, Jean-Richard Saint-Martin, Lingling Li, Michael G. Kauffman, MD PhD, Sharon Shacham, PhD MBA, Paul G. Richardson, MD, Sundar Jagannath, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3140.
https://doi.org/10.1182/blood-2019-129038
Published: 2019
Journal Articles

Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability?

Daniel Auclair, PhD, Carol Mansfield, PhD, Ajai Chari, MD, Craig E. Cole, MD, Mark A. Fiala, BS, Jonathan L Kaufman, MD, Gregory Orloff, MD, David S Siegel, MD PhD, Jeffrey A Zonder, MD, Brennan Mange, Jennifer Yesil, MS, Mehul Dalal, PhD, Joseph Mikhael, MD FRCPC, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 614.
https://doi.org/10.1182/blood-2018-99-113087
Published: 2018
Journal Articles

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study

Sundar Jagannath, MD, Jesus G. Berdeja, MD, Robert M Rifkin, MD, Craig E. Cole, MD, Michael Alan Thompson, MD PhD, Ravi Vij, MBBS, Mihaela Popa-McKiver, PhD, Rao Saleem, Oumar Sy, PhD, William Bensinger, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1991.
https://doi.org/10.1182/blood-2018-99-112077
Published: 2018
Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, MD, Craig E. Cole, MD, Leonard Heffner, MD, Ajay K Nooka, MDMPH, Ravi Vij, MBBS, Nyaya Kelkar, Akshata Sridhar, Munevver Cinar, MD, Zhengjia Chen, PhD, Zhao Chang, PhD, Sagar Lonial, MD, Jonathan L Kaufman, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2011.
https://doi.org/10.1182/blood-2018-99-119337
Published: 2018
Journal Articles

Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM

Ajai Chari, MD, Dan T. Vogl, MD, Meletios A Dimopoulos, MD, Ajay K Nooka, MDMPH, Carol Ann Huff, MD, Philippe Moreau, Craig E. Cole, MD, Joshua Richter, David Dingli, MD PhD, Ravi Vij, Sascha A Tuchman, MD, Marc S Raab, MD PhD, Katja Weisel, MD, Michel Delforge, MDPhD, David Kaminetzky, MD, Robert Frank Cornell, MD, A Keith Stewart, James Hoffman, Kelly N. Godby, MD, Terri L Parker, MD, Moshe Levy, MD, Martin Schreder, MD, Nathalie Meuleman, PhD MD, Laurent Frenzel, MD PhD, Mohamad Mohty, MD PhD, Choquet Sylvain, MD, Andrew J. Yee, MD, Maria Gavriatopoulou, MD, Luciano J Costa, MD PhD, Jatin J. Shah, MD, Carla Picklesimer, Jean-Richard Saint-Martin, Lingling Li, Michael G. Kauffman, MD PhD, Sharon Shacham, PhD MBA, Paul Richardson, Sundar Jagannath, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 598.
https://doi.org/10.1182/blood-2018-99-116663
Published: 2018
Journal Articles

Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Meletios A Dimopoulos, MD, Sara Bringhen, MD, Pekka Anttila, MD, Marcelo Capra, MD PhD, Michele Cavo, MD, Craig E. Cole, MD, Cristina J Gasparetto, MD, Vania T. M. Hungria, MD PhD, Matthew Jenner, Vladimir Vorobyev, MD PhD, Eduardo Yanez Ruiz, Jianyun Yin, Anthony Hamlett, Ravi Vij, MBBS
Journal: Blood
Blood (2018) 132 (Supplement 1): 155.
https://doi.org/10.1182/blood-2018-155
Published: 2018
Journal Articles

Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol

Daniel Auclair, PhD, Sikander Ailawadhi, Jesus G. Berdeja, MD, Xuhong Cao, Craig E. Cole, MD, Craig C Hofmeister, MDMPH, Sundar Jagannath, MD, Andrzej J. Jakubowiak, MD, Amrita Krishnan, MD, Shaji K Kumar, MD, Moshe Levy, MD, Sagar Lonial, MD, Gregory Orloff, MD, Dan Robinson, PhD, David Siegel, MD PhD, Suzanne Trudel, MD FRCP(C), Saad Z Usmani, MD, Ravi Vij, MDMBA, Jeffrey Lee Wolf, MD, Jennifer Yesil, MS, Jeffrey A Zonder, MD, Arul Chinnaiyan, MD, P. Leif Bergsagel, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 395.
https://doi.org/10.1182/blood.V130.Suppl_1.395.395
Published: 2017
Journal Articles

Understanding the Preferences of Patients and Caregivers for Relapsed/Refractory Multiple Myeloma Treatment: A Mixed-Mode Patient-Centric Approach

Daniel Auclair, PhD, Carol Mansfield, PhD, Ajai Chari, MD, Craig E. Cole, MD, Mark A. Fiala, BS, Jonathan L. Kaufman, MD, Gregory Orloff, MD, David Siegel, MD PhD, Jeff A. Zonder, MD, Brennan Mange, Jennifer Yesil, MS, Mehul Dalal, PhD, Joseph Mikhael, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5662.
https://doi.org/10.1182/blood.V130.Suppl_1.5662.5662
Published: 2017
Journal Articles

Multiple Myeloma Symptom Burden, Perceived Control, and Quality of Life: Findings from the Cancer Experience Registry

Alexandra K Zaleta, PhD, Melissa F. Miller, PhD MPH, Shauna McManus, BS, Jamese Johnson, MPH, Clare Karten, MS, Thomas W. LeBlanc, MD MA, Craig E. Cole, MD, Joanne S. Buzaglo, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5629.
https://doi.org/10.1182/blood.V130.Suppl_1.5629.5629
Published: 2017